Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British Journal of Dermatology ◽

10.1111/bjd.18029 ◽

2019 ◽

Vol 181 (6) ◽

pp. 1177-1189 ◽

Cited By ~ 5

Author(s):

D. Thaçi ◽

K. Papp ◽

D. Marcoux ◽

L. Weibel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Term Efficacy ◽

Paediatric Patients ◽

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

BioDrugs ◽

10.1007/s40259-021-00502-w ◽

2021 ◽

Author(s):

Steven R. Feldman ◽

Nataliya Reznichenko ◽

Grazyna Pulka ◽

Külli Kingo ◽

George Galdava ◽

...

Keyword(s):

Active Control ◽

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Control Phase ◽

Parallel Group ◽

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1067/mjd.2002.127247 ◽

2002 ◽

Vol 47 (6) ◽

pp. 821-833 ◽

Cited By ~ 251

Author(s):

Gerald G. Krueger ◽

Kim A. Papp ◽

Dow B. Stough ◽

Keith H. Loven ◽

Wayne P. Gulliver ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study

MD Conference Express ◽

10.1177/155989770600600307 ◽

2006 ◽

Vol 6 (3) ◽

pp. 14-14 ◽

Cited By ~ 1

Author(s):

M. Vinall ◽

N. Nishimoto

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study ◽

Receptor Monoclonal Antibody

Short- and long-term efficacy and safety of adalimumab in a pivotal phase III study in adult patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2006.10.073 ◽

2007 ◽

Vol 56 (2) ◽

pp. AB5

Keyword(s):

Plaque Psoriasis ◽

Adult Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Pivotal Phase ◽

Term Efficacy ◽

Phase Iii Study ◽

Short And Long Term

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor